Nephrolithiasis coexisting with type 2 diabetes: current concept of the features of stone formation and the effects of hypoglycemic therapy on lithogenesis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article analyzes Russian and international literature examining specific features of the pathogenesis of renal stones in the setting of carbohydrate metabolism disorders. The authors outline the renal effects of the main pharmacological groups of oral hypoglycemic drugs regarding metaphylaxis of nephrolithiasis. An increased risk of nephrolithiasis in type 2 diabetes mellitus is realized through hyperuricemia with concurrent urine acidification. Current literature is lacking studies on the effects of oral hypoglycemic drugs on urine properties. There are reports about the tendency of biguanides (metformin) to shift the urine reaction to the acid side. Derivatives of sulfonylureas, incretins and inhibitors of dipeptidyl peptidase-4, do not significantly affect the urinary acidity and urinary salt excretion. Inhibitors of sodium-glucose cotransporter type 2 (gliflozins) tend to reduce the blood level of urate, but the mechanism of this effect and the safety of these drugs in the setting of urolithiasis have not yet been investigated.

Full Text

Restricted Access

About the authors

S. K. Yarovoi

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of the NMRRC of Minzdrav of Russia; D.D. Pletnev City Clinical Hospital, Moscow Health Department

Email: yarovoy.sk@yandex.ru
Dr.Med.Sci., Leading Researcher, Clinical Pharmacologis

S. A Golovanov

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of the NMRRC of Minzdrav of Russia

Email: sergeygol124@mail.ru
Dr.Med.Sci., Head of Laboratory of Biochemical Testing

M. R. Khaziakhmetova

D.D. Pletnev City Clinical Hospital, Moscow Health Department

Email: milayshar@yandex.ru
Head of Endocrinology Department

O. V Dzhalilov

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of the NMRRC of Minzdrav of Russia

Email: osman751@mail.ru
Ph.D. Student

References

  1. Яненко Э.К., Меринов Д.С., Константинова О.В., Епишов В.А., Калиниченко Д.Н. Современные тенденции в эпидемиологии, диагностике и лечении мочекаменной болезни. Экспериментальная и клиническая урология. 2012;3:19-24
  2. Аполихин О.И., Сивков А.В., Москалева Н.Г., Солнцева Т.В., Комарова В.А. Анализ уронефрологической заболеваемости и смертности в Российской Федерации. Экспериментальная и клиническая урология. 2013;2:10-17
  3. Яровой С. К., Сивков А. В. Почечная остеодистрофия на фоне рецидивирующего нефролитиаза: выбор лекарственной терапии. Экспериментальная и клиническая урология. 2010;1:65-68
  4. Яровой С.К., Максудов Р.Р., Александров Н.С. Метаболические поражения костного скелета на фоне нефролитиаза. Экспериментальная и клиническая урология. 2012;1:24-27
  5. Яровой С.К. Современные представления о связи рецидивирующего нефролитиаза и поражения костной системы. Врач. 2009;10:22-26
  6. Бова Ф.С. Уролитиаз и сахарный диабет. Особенности диагностики и лечения. Автореф. дисс. к.м.н. М., 2010. 25 с.
  7. Wong P., Fuller P.J., Gillespie M.T., Kartsogiannis V., Strauss B.J., Bowden D., Milat F. Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporos Int. 2013;24(7):1965-1971.
  8. Zell A. Kidney Stones in Relation to Obesity and Diabetes. October 12th. Diabetes In Control, 2012 (http://www.diabetesincontrol.com/ kidney-stones-in-relation-to-obesity-and-diabetes).
  9. Spero D. Diabetes and Kidney Stones., Published July 22, 2015 (https:// www.diabetesselfmanagement.com/blog/diabetes-and-kidney-stones).
  10. Bobulescu I.A., Maalouf N.M., Capolongo G., Adams-Huet B., Rosenthal T.R., Moe O.W., Sakhaee K. Renal ammonium excretion after an acute acid load: blunted response in uric acid stone formers but not in patients with type 2 diabetes. Am J. Physiol Renal Physiol. 2013;305(10): F1498-F1503. Published online 2013 Sep 11. doi:10.1152/ ajprenal.00374.2013.
  11. Nerli R., Jali M., Guntaka A.K., Patne P., Patil S., Hiremath M.B. Type 2 diabetes mellitus and renal stones. Adv Biomed Res. 2015;4:180. doi: 10.4103/2277-9175.164012. eCollection 2015.
  12. Bellasi A., Di Micco L., Santoro D., Marzocco S., De Simone E., Cozzolino M., Di Lullo L., Guastaferro P., Di Iorio B.; UBI study investigators. Correction of metabolic acidosis improves insulin resistance in chronic kidney disease. BMC Nephrol. 2016;17(1):158.
  13. Weinberg A.E. et al. Patel C.J., Chertow G.M., Leppert J.T. Diabetic severity and risk of kidney stone disease. Eur Urol. 2014;65(1):242-47. doi: 10.1016/j.eururo.2013.03.026. Epub 2013 Mar 17.
  14. Fram E.B., Moazami S., Stern J.M. The Effect of Disease Severity on 24-Hour Urine Parameters in Kidney Stone Patients With Type 2Diabetes. Urology. 2016;87:52-59. Doi: 10.1016/j. urology.2015.10.013. Epub 2015 Oct 22.
  15. Sancak E.B., Reşorlu M., Akbas A., Gulpinar M.T., Arslan M., Resorlu B. Do Hypertension, diabetes mellitus and obesity increase the risk of severity of nephrolithiasis? Pak J Med Sci. 2015;31(3):566-71. doi: 10.12669/pjms.313.7086.
  16. Hartman C., Friedlander J.I., Moreira D.M., Elsamra S.E., Smith A.D., Okeke Z. Differences in 24-h urine composition between nephrolithiasis patients with and without diabetes mellitus. BJU Int. 2015;115(4):619- 24. doi: 10.1111/bju.12807. Epub 2014 Aug 13.
  17. Zhu W., Mai Z., Qin J., Duan X., Liu Y., Zhao Z., Yuan J., Wan S.P., Zeng G. Difference in 24-Hour Urine Composition between Diabetic and Non-Diabetic Adults without Nephrolithiasis. PLoS One. 2016;11(2):e0150006. doi: 10.1371/journal.pone.0150006. eCollection 2016.
  18. Spatola L., Angelini C., Badalamenti S., Maringhini S., Gambaro G. Kidney stones diseases and glycaemic statuses: focus on the latest clinical evidences. 05 December 2016 doi: 10.1007/s00240-016-0956-8.
  19. Аполихин О.И., Калинченко С.Ю., Камалов А.А., Гусакова Д.А., Ефремов Е.А. Мочекаменная болезнь как новый компонент метаболического синдрома. Саратовский научномедицинский журнал. 2011;7(2):117
  20. Lien T.H., Wu J.S., Yang Y.C., Sun Z.J., Chang C.J. The Effect of Glycemic Status on Kidney Stone Disease in Patients with Prediabetes. Diabetes Metab J. 2016;40(2):161-6. doi: 10.4093/dmj.2016.40.2.161.
  21. Borbély Z. Chronic kidney diseases, metformin and lactic acidosis. Vnitr Lek. 2016;62(4):299-303.
  22. Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., Novials A., Rottiers R., Rutten G.E.H.M. and Shaw K.M. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. European Journal of Clinical Investigation. 2004; 34: 535-542.
  23. Patel A., MacMahon S., Chalmers J. et al. ADVANCE Collaborative Group. Intensive blood glucose and vascular outcomes in patients with type 2 diabetes. N. Engl J. Med 2008; 358: 2560-2572.
  24. Busch M., Nadal J., Schmid M., Paul K., Titze S., Hübner S., Köttgen A., Schultheiss U.T., Baid-Agrawal S., Lorenzen J., Schlieper G., Sommerer C., Krane V., Hilge R., Kielstein J.T., Kronenberg F., Wanner C., Eckardt K.U., Wolf G. GCKD Study Investigators. Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidneydisease - cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort. BMC Nephrol. 2016;17(1):59.
  25. Шестакова М.В. Выбор безопасной сахароснижающей терапии при поражении почек у больных сахарным диабетом. Consilium Medicum. 2009;11(12):34-38
  26. Torricelli F.C., De S., Gebreselassie S., Li I., Sarkissian C., Monga M. Type-2 diabetes and kidney stones: impact of diabetes medications and glycemic control. Urology. 2014;84(3):544-48. Doi: 10.1016/j. urology.2014.02.074.
  27. Kim G., Gerich J.E., Salsali A. Empagliflozin increases genital infections but not urinary tract infections in pooled data from four pivotal phase III trials. Diabetes. 2013;62(Suppl. 1):LB21.
  28. No authors listed Empagliflozin (Jardiance). Type 2 diabetes: no rush to use this drug. Prescrire Int. 2016;25(172):145-148. Review.
  29. Davies M.J., Trujillo A., Vijapurkar U., Damaraju C.V., Meininger G. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab. Diabetes Obes Metab. 2015;17(4):426-429.
  30. Яровой С.К., Максудов Р.Р. Нарушения обмена пуринов в практике врача уролога. Экспериментальная и клиническая урология. 2013;3:88-92
  31. Яровой С.К., Максудов Р.Р. Медикаментозная терапия поражений почек, обусловленных нарушениями обмена пуринов. Лечащий врач. 2013;8:6-10
  32. Shestakova M.V. Diabetes mellitus and chronic kidney disease: Possibilities of prediction, early diagnosis, and nephroprotection in the 21st century. Ter Arkh. 2016;88(6):84-88).
  33. Wanner C., Inzucchi S.E., Lachin J.M., Fitchett D., von Eynatten M., Mattheus M., Johansen O.E., Woerle H.J., Broedl U.C., Zinman B.; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N. Engl J. Med. 2016; 375(4):323-334.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies